BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27277340)

  • 1. VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review).
    Taurone S; Galli F; Signore A; Agostinelli E; Dierckx RA; Minni A; Pucci M; Artico M
    Int J Oncol; 2016 Aug; 49(2):437-47. PubMed ID: 27277340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review).
    Song G; Li Y; Jiang G
    Oncol Rep; 2012 Dec; 28(6):1935-44. PubMed ID: 22993103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the VEGF/VEGFR axis in cancer biology and therapy.
    Rapisarda A; Melillo G
    Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-VEGF/VEGFR therapy for cancer: reassessing the target.
    Sitohy B; Nagy JA; Dvorak HF
    Cancer Res; 2012 Apr; 72(8):1909-14. PubMed ID: 22508695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF in tumor progression and targeted therapy.
    Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
    Curr Cancer Drug Targets; 2013 May; 13(4):423-43. PubMed ID: 23167597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
    Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting VEGF/VEGFRs Pathway in the Antiangiogenic Treatment of Human Cancers by Traditional Chinese Medicine.
    Zhang C; Wang N; Tan HY; Guo W; Li S; Feng Y
    Integr Cancer Ther; 2018 Sep; 17(3):582-601. PubMed ID: 29807443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
    Lopes-Coelho F; Martins F; Pereira SA; Serpa J
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
    Zhang C; Tan C; Ding H; Xin T; Jiang Y
    Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
    Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
    Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to antiangiogenic therapies.
    Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
    Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled small molecule inhibitors of VEGFR - recent advances.
    Kniess T
    Curr Pharm Des; 2012; 18(20):2867-74. PubMed ID: 22571655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy.
    Dvorak HF
    Cancer J; 2015; 21(4):237-43. PubMed ID: 26222073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor and its inhibitors.
    Verheul HM; Pinedo HM
    Drugs Today (Barc); 2003; 39 Suppl C():81-93. PubMed ID: 14988747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.